ADMS News and Press, Adamas Pharmaceuticals Inc. From 11/02/18

More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more ...

Adamas Pharmaceuticals ( ADMS -21.9% ) slumps on nearly double normal volume in reaction to its Q3 results released after the close yesterday. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more...

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Ashleigh Barreto – Director-Investor Relations and Corporate Communications Greg Went – Chairman and Chief Executive Officer Alf Merriweather – Chief F...

Adamas Pharma (NASDAQ: ADMS ): Q3 GAAP EPS of -$1.22 beats by $0.12 . Revenue of $10.6M beats by $0.46M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical compan...

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Freightcar America, Inc. (NASDAQ:RAIL), Star Bulk Carriers Corp. (NASD...

Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths ...

After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote...

Final results from a two-year open-label Phase 3 clinical trial, EASE LID 2 , evaluating Adamas Pharmaceuticals' ( ADMS -3.1% ) GOCOVRI (amantadine) in patients with Parkinson's disease (PD) showed a sustained treatment effect. The data were presented at the International Congress of P...

GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two years Results show a comparable 35% reduction from baseline in dyskinesia and OFF was achieved across all subgroups naïve to GOCOVRI as measured by MDS-UPDRS, Pa...